Associated Genetic Biomarkers
NCI Definition: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. 
Leukemias most frequently harbor alterations in DNMT3A, ASXL1, TET2, ETV6, and NPM1 .
ASXL1 Mutation, DNMT3A Mutation, TET2 Mutation, NPM1 Mutation, and ETV6 Mutation are the most common alterations in leukemia .
There are 10 clinical trials for leukemia, of which 7 are open and 3 are completed or closed. Of the trials that contain leukemia as an inclusion criterion, 8 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).
ERBB2, IDH1, and IDH2 are the most frequent gene inclusion criteria for leukemia clinical trials .
Cd22 car t-cell immunotherapy, hdm2 inhibitor hdm201, and her2 ecd+tm virus-like replicon particles vaccine avx901 are the most common interventions in leukemia clinical trials.
Significant Genes in Leukemia
ERBB2 is mutated in 1.25% of leukemia patients .
ERBB2 is an inclusion eligibility criterion in 2 clinical trials for leukemia, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and leukemia as inclusion criteria, 2 are phase 1 (1 open) .
Her2 ecd+tm virus-like replicon particles vaccine avx901, anti-pd-1/anti-lag-3 dart protein mgd013, and margetuximab are the most frequent therapies in leukemia trials with ERBB2 mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.